Methodological challenges in using routinely collected health data to investigate long-term effects of medication use during pregnancy

Therapeutic Advances in Drug Safety

Volumn 4, Issue 1, 2013, Pages 27-37

  Grzeskowiak, Luke E ^a   Gilbert, Andrew L ^a   Morrison, Janna L ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

data linkage; medication; pharmacovigilance; pregnancy; teratogen

Indexed keywords

COMPUTER SECURITY; DRUG EXPOSURE; DRUG USE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH HAZARD; HUMAN; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RELIABILITY; REVIEW; TERATOGENESIS;

EID: 84875536169     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098612470389     Document Type: Article

References (44)

1. Bakker M. Kolling P. van den Berg P. de Walle H. de Jong van den Berg L. (2008) Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 65: 600–606.
2. Berard A. Ramos E. Rey E. Blais L. St-Andre M. Oraichi D. (2007) First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80: 18–27.
3. Bohensky M. Jolley D. Sundararajan V. Evans S. Ibrahim J. Brand C. (2011) Development and validation of reporting guidelines for studies involving data linkage. Aust N Z J Public Health 35: 486–489.
4. Bohensky M. Jolley D. Sundararajan V. Evans S. Pilcher D. Scott I. (2010) Data linkage: a powerful research tool with potential problems. BMC Health Serv Res 10: 346.
5. Bronstein J. Lomatsch C. Fletcher D. Wooten T. Mei Lin T. Nugent R. (2009) Issues and biases in matching Medicaid pregnancy episodes to vital records data: the Arkansas experience. Matern Child Health J 13: 250–259.
6. Brook E. Rosman D. Holman C. (2008) Public good through data linkage: measuring research outputs from the Western Australian Data Linkage System. Aust N Z J Public Health 32: 19–23.
7. Chamberlayne R. Green B. Barer M. Hertzman C. Lawrence W. Sheps S. (1998) Creating a population-based linked health database: a new resource for health services research. Can J Public Health 89: 270–273.
8. Chambers C. Johnson K. Dick L. Felix R. Jones K. (1996) Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335: 1010–1015.
9. Cole J. Ephross S. Cosmatos I. Walker A. (2007a) Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16: 1075–1085.
10. Cole J. Modell J. Haight B. Cosmatos I. Stoler J. Walker A. (2007b) Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16: 474–484.
11. Colvin L. Slack-Smith L. Stanley F. Bower C. (2009) Pharmacovigilance in pregnancy using population-based linked datasets. Pharmacoepidemiol Drug Saf 18: 211–225.
12. Colvin L. Slack Smith L. Stanley F. Bower C. (2011) Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 91: 142–152.
13. Croen L. Grether J. Yoshida C. Odouli R. Hendrick V. (2011) Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 68: 1101–1112.
14. Crystal S. Akinciqil A. Bilder S. Walkup J. (2007) Studying prescription drug use and outcomes with Medicaid claims data strengths, limitations, and strategies. Med Care 45: S58–S65.
15. Davis R. Rubanowice D. McPhillips H. Raebel M. Andrade S. Smith D. (2007) Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 16: 1086–1094.
16. Dehlink E. Yen E. Leichtner A. Hait E. Fiebiger E. (2009) First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study. Clin Exp Allergy 39: 246–253.
17. Ehrenstein V. Sorensen H. Bakketeig L. Pedersen L. (2010) Medical databases in studies of drug teratogenicity: methodological issues. Clinical Epidemiol 2: 37–43.
18. Garbe E. Suling M. Kloss S. Lindermann C. Schmid U. (2011) Linkage of mother-baby pairs in the German pharmacoepidemiological research database. Pharmacoepidemiol Drug Saf 20: 258–264.
19. Gillman M. Oakey H. Baghurst P. Volkmer R. Robinson J. Crowther C. (2010) Effect of treatment of gestational diabetes mellitus on obesity in the next generation. Diabetes Care 33: 964–968.
20. Grzeskowiak L. Gilbert A. Morrison J. (2010) Hospital pharmacy dispensing records for pharmacoepidemiology research into late gestation exposure to antidepressants. J Pharm Pract Res 40: 265–268.
21. Grzeskowiak L. Gilbert A. Morrison J. (2011) Investigating outcomes following the use of SSRIs for treating depression in pregnancy: a focus on methodological issues. Drug Saf 34: 1027–1048.
22. Grzeskowiak L. Gilbert A. Morrison J. (2012a). Investigating outcomes associated with medication use during pregnancy: a review of methodological challenges and observational study designs. Reprod Toxicol 33: 280–289.
23. Grzeskowiak L. Gilbert A. Morrison J. (2012b) Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy. Eur J Clin Pharmacol 68: 459–467.
24. Grzeskowiak L. Gilbert A. Morrison J. (2012c) Prenatal exposure to selective serotonin reuptake inhibitors and risk of childhood overweight. J Dev Orig Health Dis 3: 253–261.
25. Hardy J. Leaderer B. Holford T. Hall G. Bracken M. (2006) Safety of medications prescribed before and during early pregnancy in a cohort of 81,975 mothers from the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 15: 555–564.
26. Herbst A. Ulfelder H. Poskanzer D. (1971) Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 284: 878–881.
27. Holman C. Bass J. Rouse I. Hobbs M. (1999) Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 23: 453–459.
28. Juhn Y. Kung A. Voigt R. Johnson S. (2011) Characterisation of children–s asthma status by ICD-9 code and criteria-based medical record review. Prim Care Respir J 20: 79–83.
29. Kallen B. (2005) Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenit Anom (Kyoto) 45: 44–51.
30. Kallen B. Nilsson E. Olausson P. (2011) Antidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records. Eur J Clin Pharmacol 67: 839–845.
31. Kelman C. Bass A. Holman C. (2002) Research use of linked health data – a best practice protocol. Aust N Z J Public Health 26: 251–255.
32. Kieler H. (2010) The Nordic Health Registers – an important source when evaluating the safety of antidepressants during pregnancy. Clin Epidemiol 2: 205–207.
33. Manning S. Davin C. Barfield W. Kotelchuck M. Clements K. Diop H. (2011) Early diagnoses of autism spectrum disorders in Massachusetts birth cohorts, 2001–2005. Pediatrics 127: 1043–1051.
34. Maschi S. Clavenna A. Campi R. Schiavetti B. Bernat M. Bonati M. (2008) Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 115: 283–289.
35. McMillen I. Robinson J. (2005) Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol Rev 85: 571–633.
36. Meador K. Baker G. Browning N. Clayton-Smith J. Combs-Cantrell D. Cohen M. (2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360: 1597–1605.
37. Mitchell A. (2003) Systematic identification of drugs that cause birth defects – a new opportunity [editorial]. N Engl J Med 349: 2556–2559.
38. Neubert A. Sturkenboom M. Murray M. Verhamme K. Nicolosi A. Giaquinto C. (2008) Databases for pediatric medicine research in Europe – assessment and critical appraisal. Pharmacoepidemiol Drug Saf 17: 1155–1167.
39. Nijenhuis C. ter Horst P. van Rein N. Wilffert B. de Jong-van den Berg L. (2012) Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: testing the hypotheses. Br J Clin Pharmacol 73: 126–134.
40. Olesen C. Sondergaard C. Thrane N. Lauge Nielsen G. de Jong-van den Berg L. Olsen J. (2001) Do pregnant women report use of dispensed medications? Epidemiology 12: 497–501.
41. Rebordosa C. Kogevinas M. Sorensen H. Olsen J. (2008) Pre-natal exposure to paracetamol and risk of wheezing and asthma in children: a birth cohort study. Int J Epidemiol 37: 583–590.
42. Sørensen H. Johnsen S. Nørgärd B. (2001) Methodological issues in using prescription and other databases in pharmacoepidemiology. Nor Epidemiol 11: 13–18.
43. Stephansson O. Granath F. Svensson T. (2011) Drug use during pregnancy in Sweden – assessed by the prescribed drug register and the medical birth register. Clin Epidemiol 3: 43–50.
44. Wakefield D. Cloutier M. (2006) Modifications to HEDIS and CSTE algorithms improve case recognition of pediatric asthma. Pediatr Pulmonol 41: 962–971.